Cachexia

Global Cancer Cachexia Industry Assessment 2017-2030: Epidemiology, Pipeline, Drugs, Products, Players and Forecasts

Retrieved on: 
Thursday, August 20, 2020
Medical specialties, Medicine, Clinical medicine, Rehabilitation medicine, Cachexia, Geriatrics, RTT, Cancer

The disease epidemiology covered in the report provides historical as well as forecasted Cancer Cachexia (CC) epidemiology segmented as the Total prevalence of Cancer Cachexia (CC), Gender-Specific cases of Cancer Cachexia (CC), and Cancer Cachexia cases based on tumor.

Key Points: 
  • The disease epidemiology covered in the report provides historical as well as forecasted Cancer Cachexia (CC) epidemiology segmented as the Total prevalence of Cancer Cachexia (CC), Gender-Specific cases of Cancer Cachexia (CC), and Cancer Cachexia cases based on tumor.
  • The drug chapter segment of the Cancer Cachexia (CC) report encloses the detailed analysis of CC marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • The analysis covers Cancer Cachexia (CC) market uptake by drugs; patient uptake by therapies; and sales of each drug.
  • Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cancer Cachexia (CC) market trend.

Cancer Cachexia (CC) - Worldwide Market Insights, Epidemiology, and Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 18, 2020
General Health, Pharmaceutical, Health, Oncology, Medical specialties, Medicine, Clinical medicine, Rehabilitation medicine, Cachexia, Geriatrics, RTT, Aging-associated diseases, Cancer

The "Cancer Cachexia (CC) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Cachexia (CC) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report also covers current Cancer Cachexia (CC) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • The disease epidemiology covered in the report provides historical as well as forecasted Cancer Cachexia (CC) epidemiology segmented as the Total prevalence of Cancer Cachexia (CC), Gender-Specific cases of Cancer Cachexia (CC), and Cancer Cachexia cases based on tumor.
  • Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cancer Cachexia (CC) market trend.

Analysis on New Product Launches in Covid-19 Related Markets-Cancer Cachexia Therapeutics Market 2019-2023 | High Prevalence and Incidence Of Cancer Cachexia To Boost Growth | Technavio

Retrieved on: 
Monday, May 4, 2020
Pharmaceutical, Health, Oncology, Cachexia, Geriatrics, Rehabilitation medicine, Benchmarking, Branches of biology

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40028

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40028
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our cancer cachexia therapeutics market report covers the following areas:
    This study identifies rising preference for novel therapies as one of the prime reasons driving the cancer cachexia therapeutics market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the cancer cachexia therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Support Immune Function and Muscle Health With Rejuvenate During Prolonged Inactivity

Retrieved on: 
Tuesday, April 7, 2020
Nutrition, Branches of biology, Articles, Nitrogen cycle, Health, Protein, Amino acid, Essential amino acid, Metabolism, Cachexia

In one study published by The Journal of Clinical Endocrinology & Metabolism, patients on bed rest gained muscle mass with Rejuvenate compared to those who experienced muscle loss who were not taking the supplement.

Key Points: 
  • In one study published by The Journal of Clinical Endocrinology & Metabolism, patients on bed rest gained muscle mass with Rejuvenate compared to those who experienced muscle loss who were not taking the supplement.
  • If your body lacks adequate essential amino acids, it can lead to a compromised immune system.
  • Without these essential amino acids, as found in Rejuvenate, synthesis of these proteins do not occur optimally and therefore can result in a compromised immune system.
  • Horner says daily intake of Rejuvenate can help prevent muscle loss and support optimal immune system function.

Actimed Therapeutics Appoints Annalisa Jenkins as Advisor

Retrieved on: 
Thursday, April 2, 2020
Medicine, Medical specialties, Branches of biology, Rehabilitation medicine, Cachexia, Geriatrics, Muscle atrophy, Colorectal cancer

LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.

Key Points: 
  • LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.
  • Robin Bhattacherjee, CEO of Actimed Therapeutics, said: "We are delighted that Annalisa has agreed to become an Advisor to Actimed.
  • Dr Jenkins is a biopharma thought leader with over 25 years of industry experience.
  • Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).

Actimed Therapeutics Appoints Annalisa Jenkins as Advisor

Retrieved on: 
Thursday, April 2, 2020
Medicine, Medical specialties, Branches of biology, Rehabilitation medicine, Cachexia, Geriatrics, Muscle atrophy, Colorectal cancer

LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.

Key Points: 
  • LONDON, April 2, 2020 /PRNewswire/ -- Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Dr Annalisa Jenkins, M.B.B.S., F.R.C.P.
  • Robin Bhattacherjee, CEO of Actimed Therapeutics, said: "We are delighted that Annalisa has agreed to become an Advisor to Actimed.
  • Dr Jenkins is a biopharma thought leader with over 25 years of industry experience.
  • Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).

Global Cancer Cachexia Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and ANI Pharmaceuticals Inc. | Technavio

Retrieved on: 
Tuesday, December 10, 2019
Pharmaceutical, Health, Oncology, Medicine, Medical specialties, Clinical medicine, Cachexia, Geriatrics, Rehabilitation medicine

In addition, the rising awareness about supportive care for cancer patients is anticipated to further boost the growth of the cancer cachexia therapeutics market.

Key Points: 
  • In addition, the rising awareness about supportive care for cancer patients is anticipated to further boost the growth of the cancer cachexia therapeutics market.
  • View the full release here: https://www.businesswire.com/news/home/20191210005805/en/
    Technavio has announced its latest market research report titled global cancer cachexia therapeutics market 2019-2023 (Graphic: Business Wire)
    Read the 148-page report with TOC on Cancer Cachexia Therapeutics Market research report by Product (Progestogens, Corticosteroids, Combination Therapies, And Other Therapeutics), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2019-2023.
  • Cancer Cachexia Therapeutics Market Product Outlook (Revenue, USD Million, 2019-2023)
    The progestogens segment is expected to grow faster than the overall market during the forecast period of 2019-2023.
  • Cancer Cachexia Therapeutics Market Regional Outlook (Revenue, USD Million, 2019-2023)
    North America was the largest geographical segment of the global cancer cachexia therapeutics market in 2018.

Immuneering to Present at the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting

Retrieved on: 
Wednesday, December 4, 2019
Medicine, Medical specialties, Branches of biology, Rehabilitation medicine, Geriatrics, Aging-associated diseases, Gross pathology, Physiology, Sarcopenia, Cachexia, Muscle atrophy, Wasting

CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Immuneering today announced the companys participation in the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting taking place in Berlin, Dec. 6-8, 2019.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Immuneering today announced the companys participation in the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting taking place in Berlin, Dec. 6-8, 2019.
  • The companys co-founder and chief executive officer, Ben Zeskind, Ph.D., MBA, will present an invited talk titled, Data-driven identification and optimization of new medicines for cancer cachexia, on Sunday, Dec. 8, 2019.
  • Details regarding the companys presentation are as follows:
    Event: 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting
    Immuneering provides world-class computational biology services to leading pharma and biotech companies while advancing its own pipeline with an initial focus on medicines for patients with cancer.
  • For more than a decade, Immuneering has established itself as a recognized leader in bioinformatics, with an extensive track record of successful partnerships, peer-reviewed publications and patent filings.

The global cancer cachexia therapeutics market at a CAGR of almost 6% during the forecast period

Retrieved on: 
Monday, October 28, 2019
Medicine, Medical specialties, Clinical medicine, Geriatrics, Rehabilitation medicine, Cachexia, Aging-associated diseases, Cancer

Global Cancer Cachexia Therapeutics Market: About this market

Key Points: 
  • Global Cancer Cachexia Therapeutics Market: About this market
    This cancer cachexia therapeutics market analysis considers sales from progestogens, corticosteroids, combination therapies, and other therapeutic products.
  • Also, our global cancer cachexia therapeutics market report looks at factors such as high prevalence and incidence of cancer cachexia, strong pipeline landscape, and rising geriatric population.
  • However, lack of approved therapies to treat cancer cachexia, side effects associated with corticosteroids, and stringent regulatory guidelines may hamper the growth of the cancer cachexia therapeutics industry over the forecast period.
  • Global Cancer Cachexia Therapeutics Market: Overview
    Globally, the cancer burden is high, which can be attributed to population growth, poverty, infections, and unhealthy lifestyle habits, among others.

Cancer Cachexia Therapeutics Market - Combination of Multiple Medical and Nutritional Therapeutic Interventions to Boost Growth Through 2019-2023 | Technavio

Retrieved on: 
Tuesday, October 22, 2019
Pharmaceutical, Health, Oncology, Rehabilitation medicine, Geriatrics, Cachexia

Growth in the cancer cachexia therapeutics market can be attributed to many segments, one of which is the product segment comprising of corticosteroids, progestogens, combination therapies, and other therapeutics.

Key Points: 
  • Growth in the cancer cachexia therapeutics market can be attributed to many segments, one of which is the product segment comprising of corticosteroids, progestogens, combination therapies, and other therapeutics.
  • View the full release here: https://www.businesswire.com/news/home/20191022005865/en/
    Technavio has announced its latest market research report titled Cancer Cachexia Therapeutics Market 2019-2023.
  • Consequently, a combination of multiple medical and nutritional therapeutic interventions are gaining traction in the market.
  • As per Technavio, the cancer cachexia therapeutics market is forecasted to grow at a CAGR of almost 6% by 2023.